AnaptysBio, Inc.
ANAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 242.8% | -19.8% | -35.6% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 58.8% | -69.9% | -48.3% | 1.2% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 50.1% | -82.6% | -74.2% | -8.8% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 19.8% | -173.5% | -141.6% | -50.5% |
| EPS Diluted | 0.52 | -1.34 | -1.28 | -0.77 |
| % Growth | 138.8% | -4.7% | -66.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |